Qaasid News

Download Our App

Author: admin

  • Culinaria’s Restaurant Weeks returns to San Antonio

    Culinaria’s Restaurant Weeks returns to San Antonio

    Biannual event will take place from Jan. 17-31

    Culinaria Restaurant Weeks (JTP210)

    SAN ANTONIO – Culinaria’s Restaurant Weeks is set to return to the Alamo City, offering two weeks of special menus and dining deals across the city.

    From Jan. 17-31, dozens of eateries will participate in the event. Participating restaurants will serve guests three-course menus for brunch, lunch and dinner throughout the Alamo City during this time.

    Hours of operation and availability of menus are subject to change.

    Here’s a list of some participating restaurants that will serve three-course menus at various price points:

    $25 three-course brunch menus

    • Box St. All Day (both locations) – 623 Hemisfair Blvd, Suite 108 and 17038 Fiesta Texas Drive, Suite 112
    • Kona Grill (both locations) – 5603 Presidio Parkway and 7400 San Pedro Ave. #1255
    • Meadow – 555 W. Bitters Road, Suite 110

    $20 and $30 three-course lunch menus

    Three-course dinner menus of $35, $45 and $55

    • Ladino – 200 E. Grayson St. #100

    For a full list of participating restaurants, click here.

    Read also:

    Copyright 2026 by KSAT – All rights reserved.

    Continue Reading

  • Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

    Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

    • Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, TEV-‘408 
    • TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac disease
    • Funding agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster

    NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-‘408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-‘408 vitiligo study provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions. Teva anticipates sharing results from TEV-‘408 trials during 2026.

    “We are delighted to enter into this second collaboration with Teva as they advance the development of TEV-‘408,” said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. “Vitiligo is a chronic autoimmune skin disease that can have a profound emotional and psychosocial burden, yet current treatment options are insufficient. Our continued collaboration underscores Royalty Pharma’s role as a long-term, trusted partner with a focus on funding innovation in potentially transformative and practice changing therapies.”

    “Strategic collaborations fuel innovation. This agreement with Royalty Pharma enables us to advance our science more efficiently and accelerate our pipeline to deliver meaningful solutions for patients worldwide,” said Richard Francis, President, and CEO of Teva. “Vitiligo represents a significant unmet need, with only one approved topical treatment currently available and no systemic options. We are dedicated to driving scientific progress that brings new, effective therapies to people living with chronic autoimmune diseases.”

    Transaction Terms

    Under the terms of the agreement, Royalty Pharma will provide Teva up to $500 million to fund ongoing development costs for TEV-‘408 in vitiligo. This is comprised of $75 million in R&D co-funding to conduct a Phase 2b study targeted to start in 2026. Based on the future results from Phase 2b in vitiligo, Royalty Pharma will have an option to provide an additional $425 million to co-fund the Phase 3 development program. If approved and launched, Teva will pay a milestone to Royalty Pharma and a royalty on worldwide net sales of TEV-‘408.

    About TEV-‘408

    TEV-‘408 is an investigational human monoclonal antibody designed to inhibit interleukin-15 (IL-15), a cytokine involved in immune-mediated pathways. TEV-‘408 has a high affinity and potency (in vitro) as well as a prolonged half-life, with a planned convenient self-administration option for patients.

    It is currently in Phase 1b (NCT06625177) for the treatment of vitiligo. The candidate is also being evaluated in a Phase 2a study (NCT06807463) for celiac disease and was granted Fast Track designation by the U.S. FDA in May 2025. By blocking IL-15 activity, TEV-‘408 aims to reduce the immune-mediated destruction of melanocytes (pigment producing cells) resulting in white patches on the skin characteristic of vitiligo or reduce the IL-15-driven intestinal inflammation and damage characteristic of celiac disease.

    About Vitiligo

    Vitiligo is a chronic autoimmune skin disease characterized by the loss of pigment-producing cells (melanocytes), resulting in white patches that can appear anywhere on the body. Affecting people of all ages, skin types, and ethnicities, vitiligo has an estimated global prevalence of 0.5% to 2% though many individuals remain undiagnosed. Beyond its physical manifestations, vitiligo can impose a significant emotional and psychosocial burden, with many people experiencing anxiety, depression, and social isolation.

    Current treatment options are limited. Only one topical therapy is approved, and its use is restricted to treating up to 10% of the body surface area. As a result, many people with vitiligo remain insufficiently treated, underscoring the need for a systemic durable, effective, and safe therapy that addresses both visible skin changes and overall quality of life.

    About Royalty Pharma plc

    Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates. For more information, visit www.royaltypharma.com.

    About Teva

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

    Royalty Pharma Forward-Looking Statements

    The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities, market growth, and plans for capital deployment. In some cases, you can identify such forward-looking statements by terminology such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “target,” “forecast,” “guidance,” “goal,” “predicts,” “project,” “potential” or “continue,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of Royalty Pharma’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. Royalty Pharma does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR on the SEC’s website at www.sec.gov.

    Teva Forward-Looking Statements

    This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop our anti-IL-15 antibody (TEV-’408) for vitiligo and for Celiac disease; our ability to successfully execute the agreement with Royalty Pharma for the funding of anti-IL-15 development for vitiligo; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generic medicines; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2025, and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned “Risk Factors” and “Forward-looking statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

    Royalty Pharma Investor Relations and Communications

    +1 (212) 883-6637
    ir@royaltypharma.com

    Teva Media Inquiries

    TevaCommunicationsNorthAmerica@tevapharm.com

    Teva Investor Relations Inquiries

    TevaIR@Tevapharm.com

    Primary Logo

    Source: Royalty Pharma plc

    Continue Reading

  • NASA won’t bring back Mars sample

    NASA won’t bring back Mars sample

    NASA canceled its plan to bring samples of rock from Mars back to Earth.

    The Perseverance rover has been traversing the surface of the Red Planet since 2021, gathering and analyzing samples, but it is just the first of two stages.

    A later, as-yet…

    Continue Reading

  • Teva Pharmaceutical Industries Ltd. – Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

    Teva Pharmaceutical Industries Ltd. – Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo


    Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

    • Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, TEV-‘408 
    • TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac disease
    • Funding agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster

    NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-‘408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-‘408 vitiligo study provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions. Teva anticipates sharing results from TEV-‘408 trials during 2026.

    “We are delighted to enter into this second collaboration with Teva as they advance the development of TEV-‘408,” said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. “Vitiligo is a chronic autoimmune skin disease that can have a profound emotional and psychosocial burden, yet current treatment options are insufficient. Our continued collaboration underscores Royalty Pharma’s role as a long-term, trusted partner with a focus on funding innovation in potentially transformative and practice changing therapies.”

    “Strategic collaborations fuel innovation. This agreement with Royalty Pharma enables us to advance our science more efficiently and accelerate our pipeline to deliver meaningful solutions for patients worldwide,” said Richard Francis, President, and CEO of Teva. “Vitiligo represents a significant unmet need, with only one approved topical treatment currently available and no systemic options. We are dedicated to driving scientific progress that brings new, effective therapies to people living with chronic autoimmune diseases.”

    Transaction Terms

    Under the terms of the agreement, Royalty Pharma will provide Teva up to $500 million to fund ongoing development costs for TEV-‘408 in vitiligo. This is comprised of $75 million in R&D co-funding to conduct a Phase 2b study targeted to start in 2026. Based on the future results from Phase 2b in vitiligo, Royalty Pharma will have an option to provide an additional $425 million to co-fund the Phase 3 development program. If approved and launched, Teva will pay a milestone to Royalty Pharma and a royalty on worldwide net sales of TEV-‘408.

    About TEV-‘408

    TEV-‘408 is an investigational human monoclonal antibody designed to inhibit interleukin-15 (IL-15), a cytokine involved in immune-mediated pathways. TEV-‘408 has a high affinity and potency (in vitro) as well as a prolonged half-life, with a planned convenient self-administration option for patients.

    It is currently in Phase 1b (NCT06625177) for the treatment of vitiligo. The candidate is also being evaluated in a Phase 2a study (NCT06807463) for celiac disease and was granted Fast Track designation by the U.S. FDA in May 2025. By blocking IL-15 activity, TEV-‘408 aims to reduce the immune-mediated destruction of melanocytes (pigment producing cells) resulting in white patches on the skin characteristic of vitiligo or reduce the IL-15-driven intestinal inflammation and damage characteristic of celiac disease.

    About Vitiligo

    Vitiligo is a chronic autoimmune skin disease characterized by the loss of pigment-producing cells (melanocytes), resulting in white patches that can appear anywhere on the body. Affecting people of all ages, skin types, and ethnicities, vitiligo has an estimated global prevalence of 0.5% to 2% though many individuals remain undiagnosed. Beyond its physical manifestations, vitiligo can impose a significant emotional and psychosocial burden, with many people experiencing anxiety, depression, and social isolation.

    Current treatment options are limited. Only one topical therapy is approved, and its use is restricted to treating up to 10% of the body surface area. As a result, many people with vitiligo remain insufficiently treated, underscoring the need for a systemic durable, effective, and safe therapy that addresses both visible skin changes and overall quality of life.

    About Royalty Pharma plc

    Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates. For more information, visit www.royaltypharma.com.

    About Teva

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

    Royalty Pharma Forward-Looking Statements

    The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities, market growth, and plans for capital deployment. In some cases, you can identify such forward-looking statements by terminology such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “target,” “forecast,” “guidance,” “goal,” “predicts,” “project,” “potential” or “continue,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of Royalty Pharma’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. Royalty Pharma does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR on the SEC’s website at www.sec.gov.

    Teva Forward-Looking Statements

    This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop our anti-IL-15 antibody (TEV-’408) for vitiligo and for Celiac disease; our ability to successfully execute the agreement with Royalty Pharma for the funding of anti-IL-15 development for vitiligo; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generic medicines; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2025, and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned “Risk Factors” and “Forward-looking statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

    Royalty Pharma Investor Relations and Communications

    +1 (212) 883-6637
    ir@royaltypharma.com

    Teva Media Inquiries

    TevaCommunicationsNorthAmerica@tevapharm.com

    Teva Investor Relations Inquiries

    TevaIR@Tevapharm.com

    Primary Logo

    Source: Royalty Pharma plc

    Continue Reading

  • DNA disproves most theories about the ‘Beachy Head Woman’

    DNA disproves most theories about the ‘Beachy Head Woman’

    The Beachy Head Woman study shows a 2,000-year-old skeleton at Beachy Head in southern England belonged to a local woman in Roman Britain.

    A London museum team used newer DNA and chemistry tests to revisit a debate that shaped public views of…

    Continue Reading

  • North Korea’s Kim Yo Jong urges South Korea to investigate drone incidents

    North Korea’s Kim Yo Jong urges South Korea to investigate drone incidents

    SEOUL–North ‌Korea’s Kim Yo Jong, ‍the powerful sister of leader Kim Jong Un, urged South Korea to investigate recent drone incidents over North Korean airspace, in a statement carried by state media…

    Continue Reading

  • Bauer to Lead Football Strength and Conditioning Programming

    Bauer to Lead Football Strength and Conditioning Programming

     

    FORT WORTH – Following a two-year run at Troy and five years at Houston, Darl Bauer has been named TCU’s Assistant Athletic Director for Football Human Performance, the department announced on Sunday.

     

    In this role, Bauer will lead a…

    Continue Reading

  • Potential measles exposure identified in Fayette County

    Potential measles exposure identified in Fayette County

    Potential measles exposure identified in Fayette County

    Published 5:00 pm Sunday, January 11, 2026

    …

    Continue Reading

  • How to Improve Your Sleep Hygiene for Better Health, According to Sleep Experts

    How to Improve Your Sleep Hygiene for Better Health, According to Sleep Experts

    Key Takeaways

    • Sleep hygiene is about daily habits and bedroom environment—not just how long you sleep.
    • Consistent bedtimes, limiting screens, and reserving your bed for sleep can dramatically improve sleep quality.
    • Small, gradual changes to your…

    Continue Reading

  • Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

    BOSTON–(BUSINESS WIRE)–Jan. 11, 2026–
    Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT.

    “2025 was a year of strong commercial execution and rapid R&D progress, setting up the company for continued growth and many important milestones in 2026,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Building on this momentum, we are focused on expanding our commercial reach in multiple disease areas; advancing the emerging renal franchise, including the potential near-term launch of povetacicept; and progressing our mid- and late-stage clinical pipeline. Vertex is well positioned to serve many more patients with our expanding portfolio of transformative medicines, and in so doing, deliver sustained growth and long-term value for shareholders.”

    Disease Areas with Approved Medicines

    Cystic Fibrosis (CF)

    • ALYFTREK®: ALYFTREK is now approved in the U.S., the United Kingdom (U.K.), the European Union (EU), Canada, New Zealand, Switzerland, and Australia for people with CF 6 years and older who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ALYFTREK. Eligible patients in the U.S., England, Ireland, Germany, Denmark, Northern Ireland, Norway, and Wales currently have reimbursed access to ALYFTREK, and Vertex is working to secure access for eligible patients in additional countries. Vertex plans to share data from the global study of ALYFTREK in children 2 to 5 years of age and submit to global regulators in 2026. Vertex expects to initiate a pivotal study of ALYFTREK in children 1 to 2 years of age in 2026.

    • TRIKAFTA®: Following positive results from the study of TRIKAFTA in patients one year to less than two years of age, reported in November 2025, Vertex expects to submit for approvals in this age group to global regulators, beginning in the first half of 2026.

    • Next-generation CFTR modulators: Vertex has advanced VX-828, the first of the next-generation 3.0 CFTR corrector class, into a study in people with CF. Vertex expects to complete enrollment and dosing in this study and share data in the second half of 2026. Vertex also advanced VX-581, another corrector in this class, into a Phase 1 study in healthy volunteers.

    • VX-522: Vertex is working to complete dosing in the multiple ascending dose (MAD) portion of the Phase 1/2 study of VX-522 and share data in the second half of 2026. VX-522 is a CFTR mRNA therapeutic that Vertex is developing in collaboration with Moderna for the approximately 5,000 people with CF who cannot benefit from CFTR modulators.

    • Epidemiology and market opportunity update: Vertex increased its estimates for the number of people with CF in all target markets from approximately 109,000 to approximately 112,000, which includes an increase from 94,000 to approximately 97,000 people with CF in the core markets of U.S., Europe, Australia, and Canada.

    Severe Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) – CASGEVY®

    • CASGEVY is approved in the U.S., the U.K., the EU, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Qatar, Canada, Switzerland, the United Arab Emirates, and Kuwait for patients 12 years and older with SCD or TDT.

    • Vertex realized its goal for greater than $100 million of CASGEVY revenue in 2025, reflecting more than 60 patients receiving infusions of CASGEVY.

    • At the American Society of Hematology (ASH) annual meeting in December 2025, Vertex presented positive data from the pivotal studies of CASGEVY in children ages 5 to 11 years old with SCD or TDT. Vertex expects to begin submitting in the first half of 2026 for approvals from global regulators. The U.S. Food and Drug Administration (FDA) awarded Vertex a Commissioner’s National Priority Voucher for this pediatric submission, accelerating the timeline for review once the submission is complete.

    • Taken together, Vertex expects these advances will result in significant CASGEVY revenue growth in 2026 and beyond.

    Acute Pain – JOURNAVX®

    • JOURNAVX (suzetrigine) is approved in the U.S. for the treatment of moderate-to-severe acute pain in adults.

    • Since FDA approval on January 30, 2025, and pharmacy availability in March 2025, more than 500,000 JOURNAVX prescriptions were written and filled in 2025 across both hospital and retail settings.

    • Vertex secured commercial coverage for JOURNAVX with the remaining large national pharmacy benefit manager (PBM) and now has secured access for JOURNAVX with all three national PBMs. As of January 2026, over 200 million individuals now have access to JOURNAVX across commercial and government payers, representing two-thirds of U.S. covered lives – a significant achievement in the first year of product launch.

    • Vertex plans to complete a regulatory submission in Canada for JOURNAVX for the treatment of moderate-to-severe acute pain in adults in the first half of 2026.

    • With positive feedback on JOURNAVX’s efficacy and tolerability and strong progress with payers, hospital, and physician adoption, Vertex expects the number of JOURNAVX prescriptions to more than triple in 2026 versus 2025.

    Programs in Pivotal Development

    Peripheral Neuropathic Pain (PNP)

    • Vertex expects to complete enrollment in both Phase 3 studies of suzetrigine in diabetic peripheral neuropathy (DPN), a form of peripheral neuropathic pain (PNP), by the end of 2026.

    • Vertex also continues to enroll and dose patients in a Phase 2 study of VX-993 in DPN.

    • Epidemiology and market opportunity update: Vertex increased its estimates for the number of people with DPN in the U.S. from approximately 2 million to approximately 2.5 million, which reflects the aging U.S. population and increased prevalence of chronic pain in older age groups.

    IgA Nephropathy (IgAN), Primary Membranous Nephropathy (pMN) and other B Cell-Mediated Diseases – povetacicept

    • In the fourth quarter of 2025, Vertex initiated the rolling biologics license application (BLA) filing for U.S. accelerated approval of povetacicept in IgAN with submission of the first module. Vertex remains on track to complete the submission in the first half of 2026. Vertex is using a priority review voucher to expedite the review of the povetacicept BLA from ten months to six months, and the FDA has granted Breakthrough Therapy Designation for povetacicept in IgAN. The RAINIER Phase 3 study completed full enrollment in November.

    • Vertex continues to enroll and dose patients in the Phase 2/3 OLYMPUS pivotal study of povetacicept in patients with pMN. The FDA has granted Fast Track designation for povetacicept in pMN, and the EMA has granted Priority Medicines (PRIME) designation.

    • Epidemiology and market opportunity update: Vertex increased its estimates for the number of people with IgAN in the U.S. and Europe from approximately 300,000 to approximately 330,000 and estimates the global diagnosed population exceeds 1.5 million. For pMN, Vertex estimates the disease impacts approximately 150,000 people in the U.S. and Europe and more than 600,000 globally.

    APOL1-Mediated Kidney Disease (AMKD) – inaxaplin

    • In September, Vertex completed enrollment in the interim analysis cohort of the AMPLITUDE Phase 2/3 trial of inaxaplin in patients with primary AMKD and will conduct the pre-planned interim analysis once this cohort reaches 48 weeks of treatment. Vertex expects to share data from the interim analysis in late 2026 or early 2027. The AMPLITUDE study is on track to complete full enrollment in the second half of 2026.

    Type 1 Diabetes (T1D)

    • Vertex has completed enrollment in the Phase 1/2/3 study of zimislecel in people with T1D and has temporarily postponed completion of dosing in the study, pending an ongoing internal manufacturing analysis.

    • Zimislecel has been granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration, PRIME designation from the EMA, Breakthrough Medicine designation from the Kingdom of Saudi Arabia, and has secured an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

    Programs in Mid-Stage Clinical Development

    Autosomal Dominant Polycystic Kidney Disease (ADPKD) – VX-407

    • Vertex is enrolling and dosing patients with ADPKD in the AGLOW Phase 2 proof- of-concept study. AGLOW is a 24-patient single-arm study that will evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV).

    Myotonic Dystrophy Type 1 (DM1) – VX-670

    • Vertex continues to enroll and dose the MAD portion of the GALILEO global Phase 1/2 clinical trial of VX-670 in people with DM1; the study is assessing both safety and efficacy. Vertex is on track to complete enrollment and dosing in the trial in mid-2026.

    Generalized Myasthenia Gravis (gMG) – povetacicept

    • Vertex expects to initiate a Phase 2 study of povetacicept for the treatment of generalized myasthenia gravis, another B cell-mediated disease, in the first half of 2026.

    • Epidemiology and market opportunity update: Vertex estimates that the number of people with gMG is approximately 175,000 in the U.S. and Europe and more than 300,000 globally.

    Additional Earlier Stage R&D Programs

    • Consistent with its overall strategy, Vertex takes a portfolio approach to all of its programs, with additional assets or approaches in CF, SCD, TDT, pain, AMKD, T1D, DM1, and ADPKD in earlier stages of development. Additionally, Vertex is working on preclinical molecules with the potential to expand its leadership in existing disease areas, including assets targeting improved immunosuppression for zimislecel, gentler conditioning for CASGEVY, and inhibition of NaV1.7 in pain.

    J.P. Morgan Healthcare Conference Presentation and Webcast

    Dr. Kewalramani will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT. A live webcast of management’s remarks will be available through the Vertex website, www.vrtx.com, in the “Investors” section under the “News and Events” page. A replay of the conference webcast will be archived on the company’s website.

    About Vertex

    Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, and myotonic dystrophy type 1.

    Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America, and the Middle East. Vertex is consistently recognized as one of the industry’s top places to work, including 16 consecutive years on Science magazine’s Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex’s history of innovation, visit at www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X.

    Special Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements by Reshma Kewalramani, M.D., and statements about expectations for the company’s CF program, including with respect to commercial expansion, expectations for advancement of the emerging renal franchise, plans to progress the company’s mid- and late-stage clinical pipeline, and beliefs that the company is well-positioned to serve more patients and deliver value for shareholders, expectations to expand access to ALYFTREK in additional countries, share data from the global study of ALYFTREK in patients 2 to 5 years of age and submit to global regulators in 2026, plans to initiate a pivotal study of ALYFTREK in patients 1 to 2 years of age in 2026, expectations to submit to global regulators for approval for TRIKAFTA in patients one year to less than two years of age beginning in the first half of 2026, expectations to complete enrollment and dosing in the VX-828 study of people with CF and share data in the second half of 2026, expectations with respect to Vertex’s next-generation, 3.0 CFTR corrector class, plans to complete dosing in the MAD portion of the Phase 1/2 study of VX-522 and share data from the study in the second half of 2026, expectations that VX-522 may treat the ~5,000 people with CF who cannot benefit from CFTR modulators, the company’s beliefs regarding CF epidemiology and market opportunities, expectations for CASGEVY, including with respect to beginning global regulatory submissions in the first half of 2026, beliefs regarding an accelerated timeline for review, and expectations for significant CASGEVY revenue growth in 2026 and beyond, expectations with respect to JOURNAVX, including with respect to tripling the number of JOURNAVX prescriptions in 2026 versus 2025, and plans to complete regulatory submissions in Canada for JOURNAVX in the first half of 2026, expectations regarding Vertex’s PNP program, including with respect to completing enrollment in both Phase 3 studies of suzetrigine in DPN by the end of 2026, plans with respect to the Phase 2 study of VX-993 in DPN, and the company’s beliefs regarding DPN epidemiology and market opportunities, expectations with respect to povetacicept and Vertex’s programs in IgAN, pMN, and other B cell-mediated diseases, including with respect completion of the BLA submission for povetacicept in IgAN in the U.S. in the first half of 2026, the anticipated expedited review period, plans to continue to enroll and dose the Phase 2/3 OLYMPUS pivotal study of povetacicept in pMN, expectations to initiate a Phase 2 study of povetacicept in gMG in the first half of 2026, and the company’s beliefs regarding epidemiology and market opportunities for IgAN, pMN, and gMG, expectations regarding inaxaplin and Vertex’s AMKD program, including with respect to conducting the pre-planned interim analysis once the cohort reaches 48 weeks of treatment, expectations to share data from the interim analysis in late 2026 or early 2027, and completing full enrollment in the AMPLITUDE study in the second half of 2026, expectations with respect to zimislecel and Vertex’s T1D program, including expectations regarding the temporary postponement of the Phase 1/2/3 study of zimislecel and plans for the ongoing internal manufacturing analysis, expectations regarding VX-407 and Vertex’s ADPKD program, and expectations regarding VX-670 and Vertex’s DM1 program, including with respect to completing enrollment and dosing in the GALILEO study in mid-2026, and the company’s beliefs with respect to additional assets or approaches in CF, SCD, TDT, pain, AMKD, T1D, DM1, and ADPKD, including working on preclinical molecules with the potential to expand Vertex’s leadership in existing disease areas, including assets targeting improved immunosuppression for zimislecel, gentler conditioning for CASGEVY, and inhibition of NaV1.7 in pain. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company’s beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the company may be unable to successfully commercialize its marketed products, that data from a limited number of patients may not be indicative of final clinical trial results, that clinical trial data might not be available on the expected timeline, that data from the company’s research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, or other reasons, that anticipated commercial launches may be delayed, if they occur at all, that external factors may have different or more significant impacts on the company’s business or operations than the company currently expects, that regulatory submissions may not occur on the anticipated timeline, or at all, that discussions with regulators may cause delays in the company’s pipeline programs, and other risks listed under the heading “Risk Factors” in Vertex‘s most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at www.sec.gov and available through the company’s website at www.vrtx.com. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

    (VRTX-GEN)

    Vertex Pharmaceuticals Incorporated

    Investors:

    InvestorInfo@vrtx.com

    or

    617-961-7163

    Media:

    mediainfo@vrtx.com

    or

    International: +44 20 3204 5275

    or

    U.S.: 617-341-6992

    Source: Vertex Pharmaceuticals Incorporated

    Continue Reading